Comparative aspects of canine and human inflammatory breast cancer

Raposo, Teresa P; Arias-Pulido, Hugo; Chaher, Nabila; Fiering, Steven; Argyle, David; Prada, Justina; Pires, Isabel; Queiroga, Felisbina L.

doi:10.1053/j.seminoncol.2017.10.012

Cited by 40 publications

(55 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4 Canine mammary carcinoma has been shown to be a valid model for the study of breast cancer in women. [9][10][11] For this reason, the molecular classification used in human medicine has been used to establish an immunohistochemical classification of canine mammary carcinoma. 9 This classification includes the expression of oestrogen receptor alpha (ERα) and progesterone receptor (PR) and the overexpression of human epidermal growth factor receptor 2 (HER2) in an attempt to redefine the classification of mammary neoplasms, predict their prognosis and provide therapeutic guidelines for routine clinical practice.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours

Pastor

Ezquerra

Santella

et al. 2020

Vet Comparative Oncology

View full text Add to dashboard Cite

Canine mammary carcinoma represents a model for the study of human breast cancer, although the prognostic value of various clinical, histological and immunohistochemical parameters has shown contradictory results. A prospective study, through a 4-year followup, was performed in 77 patients with mammary carcinoma to analyse the association between histological diagnosis, grade of malignancy, peritumoral and vascular invasion. We have also performed immunohistochemistry for the expression of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and cyclooxygenase-2 (COX-2) that define human biomarkers of disease progression and treatment response. An association between histological diagnosis and clinical stage was observed with a high proportion of complex carcinoma classified as stage I. There was a higher proportion of ER + /PR + /HER2 − tumours in stage I. In contrast, triple-negative tumours (ER − /PR − /HER2 −) were found mainly in advanced clinical stages and were associated with vascular and peritumoral invasion. The tumours included in group VII (carcinosarcoma/ adenosquamous carcinoma/other special types of carcinoma) had a higher expression of COX-2. The univariate analysis showed that those patients with complex carcinoma had the lowest incidence of metastases and the highest probability of survival. In contrast, a high proportion of patients with anaplastic/inflammatory carcinoma developed metastases and showed the lowest probability of survival. In addition, the estimated survival time was shorter for those patients with triple-negative tumours and those with high COX-2 expression. However, in the multivariate analysis, only the peritumoral invasion maintained its prognostic significance. In conclusion, in our study anaplastic/inflammatory carcinomas had the worst prognosis with a high proportion of triple-negative tumours in this category.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Canine mammary carcinoma has been shown to be a valid model for the study of breast cancer in women 9‐11 . For this reason, the molecular classification used in human medicine has been used to establish an immunohistochemical classification of canine mammary carcinoma 9 .…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours

Pastor

Ezquerra

Santella

et al. 2020

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…The limitation of such models, however, is that tumors are usually artificially induced or implanted and thus do not represent spontaneously generated tumors that occur naturally. Canine models have been used increasingly to bridge the gap between murine studies and human clinical evaluation because they afford a way to study naturally occurring tumors that mimic the clinical situation in the human setting [ 16 , 17 ]. A limitation of canine models, however, is the availability of analytical reagents that allow extensive evaluation of immune response at the cellular level [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

“…Canine models have been used increasingly to bridge the gap between murine studies and human clinical evaluation because they afford a way to study naturally occurring tumors that mimic the clinical situation in the human setting [ 16 , 17 ]. A limitation of canine models, however, is the availability of analytical reagents that allow extensive evaluation of immune response at the cellular level [ 17 ]. In this work, we utilized acute cytokine response levels as a measure of subject response to vaccination.…”

Section: Discussionmentioning

confidence: 99%

Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects

Goodrich

Weston²,

Hartson

et al. 2020

Journal of Immunology Research

View full text Add to dashboard Cite

Background. We are developing cancer immunotherapy based on the use of autologous tumor tissue that has been rendered replication-incompetent but maintains phenotype and metabolic activity post-preparation. Aim. The aim of this study was to evaluate safety and tolerance to injection of the inactivated tumor cell and adjuvant preparation (Innocell™) within 24 hours of administration in a pilot study in canine patients with solid organ tumors. Methodology. Three canine patients demonstrating accessible solid organ tumors of various types were assessed in this study. The local site injection was monitored post-treatment. Clinical signs of adverse reactions were monitored for 24 hours post-treatment. Blood samples were taken pre-treatment and at 8 and 24 hours post-treatment for all subjects. One subject provided samples at 7 days post-treatment. All blood samples were analyzed for cytokine content for both immune system-associated and tumor-associated cytokines. Results. No signs of adverse reactions at the site of injection or systemically were observed in the study period. A slight fever and lethargy were reported in one subject by the owner post-vaccination. Immune system-associated cytokine levels in two of the three animals were elevated post-treatment. Tumor-associated cytokine levels in all three subjects declined post-treatment from baseline levels with the effect most prominent in the subject with a non-excised tumor. Conclusion. Subcutaneous injection of the inactivated tumor cells and adjuvant was well tolerated in this pilot study. Cytokine responses observed were in line with the intended use of the treatment in stimulating immune response without adverse clinical observations. Additional evaluation is warranted.

show abstract

“…In addition, canines are a promising model for human cancers, as they age faster than humans but share the same environments and have high levels of phenotypic diversity [3]. Raposo and colleagues emphasized that canine inflammatory mammary carcinoma (CIMC) can serve as a very good model of human inflammatory breast cancer (IBC) [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Molecular Mechanisms of Canine Cancers

Cao¹,

Kouznetsova²,

Tsigelny³

2019

obm genet

View full text Add to dashboard Cite

Cancer is the leading cause of death in dogs, and 50 percent of dogs over the age of 10 develop cancer at some point. The most common cancers in dogs include lymphoma, mast cell tumors, osteosarcoma, mammary gland tumors, and melanoma, and many of them share marked similarities with their human counterparts. Although canines are afflicted with many of the same types of cancers as humans, the genetic basis behind these cancers are not as well understood. Thus, the aim of this study is to elucidate some of the molecular mechanisms behind canine cancers. Canine lymphoma mutation patterns generally vary with the type of lymphoma afflicted-B-cell lymphomas have mutations in the alternative NF-kB pathway including MAP3K14, whereas in T-cell lymphomas the mTOR pathway in boxers and cellular metabolism genes in golden retrievers are affected. Mast cell tumors are largely traced to internal tandem duplications and deletions in the juxtamembrane domain of the proto-oncogene c-KIT. In osteosarcoma, mutations in RB1 and TP53 (especially G: C->A:T transitions in exons 4 and 5), as well as CDK4 inhibitors CDKN2A/B are common. Mammary gland tumors are associated with BRCA2 underexpression due to reading frame shift and mutations in BRC repeat 3. Lastly, deletion or underexpression of p16 and PTEN and altered expression of cell-cell adhesion molecules are common factors in the development of melanoma. The genes identified were then studied to identify more key amino acid mutations that changed protein products and promoted tumorigenesis. Genes that altered expression levels of proteins were analyzed separately. Both sets of candidate genes were then analyzed with the Database for Annotation, Visualization, and Integrated Discovery (DAVID) in order to elucidate the molecular pathways involved in canine cancers and identify more genes possibly involved in tumorigenesis. The proposition of this review is that treatments for both canine and human cancers would be enhanced by comparative genomic studies.

show abstract

Comparative aspects of canine and human inflammatory breast cancer

Cited by 40 publications

References 121 publications

Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours

Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours

Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects

Molecular Mechanisms of Canine Cancers

Contact Info

Product

Resources

About